Back to Search
Start Over
Cytotoxicity of a naturally occuring spirostanol saponin, progenin III, towards a broad range of cancer cell lines by induction of apoptosis, autophagy and necroptosis.
- Source :
-
Chemico-biological interactions [Chem Biol Interact] 2020 Aug 01; Vol. 326, pp. 109141. Date of Electronic Publication: 2020 May 23. - Publication Year :
- 2020
-
Abstract
- This study was aimed to investigate the cytotoxic potential of a natural compound, progenin III on a broad range of cancer cell lines, including various sensitive and drug-resistant phenotypes. The cytotoxicity, progenin III-induced autophagic, ferroptotic and necroptotic cell death were evaluated by the resazurin reduction assay (RRA). Spectrophotometric analysis of caspases activity was performed using caspase-Glo assay. Flow cytometry was applied for cell cycle analysis (PI staining), apoptosis (annexin V/PI staining), mitochondrial membrane potential (MMP) (JC-1) and reactive oxygen species (ROS) (H <subscript>2</subscript> DCFH-DA). Progenin III and the reference molecule, doxorubicin exerted cytotoxic effects towards the 18 cancer cell lines tested including animal and human cell lines. The IC <subscript>50</subscript> values obtained ranged from 1.59 μM (towards CCRF-CEM leukemia cells) to 31.61 μM (against the BRAF-V600E homozygous mutant SKMel-28 melanoma cells) for progenin III. Normal sensitivity was achieved with CEM/ADR5000 cells and HCT116p53 <superscript>-/-</superscript> adenocarcinoma cells respectively compared to their sensitive congeners CCRF-CEM cells and HCT116 p53 <superscript>+/+</superscript> cells. Progenin III induced apoptosis in CCRF-CEM cells mediated by caspases 3/7 activation, MMP alteration and increase ROS production, and otherwise autophagy and necroptosis. Progenin III is a potential anticancer molecule that deserves further investigations to develop a novel drug to combat malignant diseases including refractory cancers.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Subjects :
- Antineoplastic Agents, Phytogenic pharmacology
Caspases metabolism
Cell Cycle drug effects
Cell Death drug effects
Cell Line, Tumor
Doxorubicin pharmacology
Drug Resistance, Neoplasm drug effects
HCT116 Cells
Hep G2 Cells
Humans
Melanoma, Experimental
Membrane Potential, Mitochondrial drug effects
Plant Extracts pharmacology
Reactive Oxygen Species metabolism
Apoptosis drug effects
Autophagy drug effects
Necroptosis drug effects
Saponins pharmacology
Spirostans pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1872-7786
- Volume :
- 326
- Database :
- MEDLINE
- Journal :
- Chemico-biological interactions
- Publication Type :
- Academic Journal
- Accession number :
- 32454006
- Full Text :
- https://doi.org/10.1016/j.cbi.2020.109141